Panels

Panel sessions I: 10:55 – 12:10, Monday, June 17

PN01 - HTA Agency Collaboration In The Use Of Real World EvidenceThere is significant interest in using Real World Data/Evidence in assessments conducted by HTA agencies. In order to develop a more standardized approach, a Joint HTA Agency RWE Task Group was established with representation from INAHTA, EUnetHTA, HTAsiaLink, and RedETSA. Panelists will discuss components of their joint action plan for harmonization and collaboration in the use of RWE.
PN02 - Early HTA: The Fast-track To Evidence And Adoption Of Innovative Technologies?To improve the availability of valuable innovative health technologies, the innovation gap must be reduced. That requires early assessment methods and processes that can improve the efficiency of the research and development process. Based on real-world case studies, the panel discusses how early HTA has a vital role in addressing uncertainty and providing step-wise technology development support.
PN04 - VALIDATE: VAlues In Doing Assessments Of Healthcare TechnologiesHTA is where facts and values meet. HTA experts should be able to point out what we need to know about a healthcare technology, given a commitment to a range of values. The VALIDATE project aims to develop learning materials for students of HTA, providing them with opportunities to gain hands-on experience with this integrative approach to HTA.
PN06 - Taking Value Based Decision Making In Emerging Markets To The Next Level: From Theory to PolicyThe focus of this panel will be on value-based decision making for pharmaceutical policies in emerging markets relating to listing, pricing, reimbursement, or purchasing. The panel will present and discuss with the audience an ongoing initiative based on Multi-Criteria Decision Analysis (MCDA) principles aiming to support local players to ensure that their decisions help to meet the country’s policy objectives.
PN07 - The Value Of Patient-based Evidence In HTA Beyond 2020Patient-based evidence arises from robust methodologies and can be critically appraised. Its value in decision-making is being seen in recent recommendations from the FDA and WHO. However, patient-based evidence is not well understood in the HTA community. This panel will explore these issues and consider how we enhance use of patient-based evidence to better understand issues of value in HTA.
PN08 - Unified vs. Localized HTA Systems: What Are The Considerations?Differing perspectives on how the trend towards more globalized health technology assessments has impacted market access.
PN09 - Initiatives To Guide Patient Preference Elicitation Within HTA – Duplication Or Alignment Of Effort?As interest in generating patient-based evidence through patient preference data grows, so does the number of task forces and working groups involved in providing practical guidance on this subject. This panel session will explore if these different initiatives have harmonized or overlapping objectives and whether the outputs are likely to facilitate or confuse the field of patient preference research.
PN10 - HTA In Europe Post 2020The objective of the panel is to explore potential future scenarios for HTA in the European Union in light of the most recent legislative and scientific developments, and to provide the audience with opinions and perspectives from different stakeholders (European Commission, EUnetHTA, industry and patients).
PN11 - Is MCDA For HTA Finally Ready For Prime Time?There is an increased interest in the use of multi-criteria decision analysis (MCDA) in HTA decision-making. However, MCDA has been strongly criticized for being 'entirely mechanistic' and ignoring opportunity costs. A recent paper, authored by 20+ MCDA experts, responds to this criticism and provides guidance. This session aims to explore whether MCDA for HTA is finally ready for prime time.
PN13 - Using Ex Ante HTA To incentivise R&D For TB: Will The MVAC Engage The BRICS And Industry?Efforts to end TB have stalled. The burden is concentrated in the BRICS. A new Market-driven Value-based Advance Commitment (MVAC) can incentivise R&D.  The key is a purchase commitment based on ex-ante HTA, estimating prices and volumes for a universal regimen matching a target product profile and BRICS countries ability and willingness to pay.

Panel sessions II: 10:30 – 11:45 Tuesday, June 18
PN14 - Defining HTA: How To Develop A Common Understanding And Consensus On The Language and Methods Of HTAWho we are as HTA practitioners, policy-makers and industry is defined by the language and methods we use to describe and deliver HTA. This session explores the challenges encountered when producing common methodologies and a shared lexicon. We discuss processes used to develop new definitions for ‘HTA’, and ‘RWE’, and when gaining consensus for INTEGRATE and the HTA Core model.
PN15 - HTx: Creating A Framework For Next Generation HTA In EuropeIn 2019, we started a new European Horizon2020 project (acronym HTx), that aims to develop new HTA methodologies to deliver more customized information on the effectiveness and cost-effectiveness of complex and personalised combinations of health technologies. During this panel we present the aims of this project and discuss with the audience what is needed for a framework for next generation.
PN16 - Using Real World Data To Improve HTA – Experiences From Sweden And Future PotentialThis panel session will explore the usefulness of Real World Data (RWD) in HTA to analyze real world outcomes and costs; to describe current practices and identify know-do gaps; and to include patients’ perspectives on the use of health and social interventions. Examples from Sweden will be presented illustrating how RWD does not replace but complete evidence from RCTs.
PN17 - How Can Networks Support HTA Implementation In The Middle East And North Africa?An international team of HTA activists gives an overview of the latest initiatives and developments in HTA in the MENA region. The way forward, emphasizing the importance of international collaboration will be discussed with a panel representing international networks and the public sector in the region. This panel will explore the potential for HTA beyond 2020 in the MENA region.
PN18 - CAR-Ts And Post-2020 ChallengesFfor HTA And PricingThe panel will provide different international perspectives (public and private insurers, manufacturers, ICER) on the challenges of health technology assessment (HTA) for CAR-Ts.  We anticipate that these and similar cell therapies for cancer treatment will become commonplace in the next decade.  Will international collaboration be the way forward?
PN19 – How Should HTA Groups Assess Tumor-Agnostic Therapies In Oncology?Advances in science are bringing forward cancer therapies with transformative outcomes demonstrated by means of basket trials with low number of patients. HTA bodies do not have experience assessing agents that target oncogenic drivers that are tumor-agnostic. As the tumor-agnostic development pipeline is growing, there is an urgent need to understand how they challenge traditional HTA and the potential solutions.
PN20 - Strengthening The Interaction Between Clinical Research And HTA To Support Decision-makingHealth technology assessments may offer a systematic tool for identification of evidence gaps in clinical research. Thus, there is a potential to use such information in a more efficient way to feed into further research to support decision-making and guidelines. In order to facilitate this mechanism, there is a need to promote closer collaboration between clinical research and HTA communities.
PN21 - Improving Access To High Cost Technologies; Findings From The HTAi 2018 Asia Policy Forum.Providing access to high cost technologies is a challenge for many countries in the Asia region. Without development of policies and consideration of mechanisms such as managed entry schemes (MES), inequity in access will increase. These issues in Asia have been discussed at the HTAi Asia Policy Forum; these will be presented and expanded on in this session.
PN22 - What’s Needed To Develop Better Multi-stakeholder Collaboration In HTA Beyond 2020?Better multi-stakeholder collaborative approaches are needed to address the challenges of health system sustainability beyond 2020. Through exploration of collaborative approaches in HTA and health policy, this panel will reflect on what makes collaborations successful and explore areas of HTA that could benefit most from news styles of collaboration.
PN23 - HTA & Medical Devices: The Past, Present & Future Of Medical Device Value AssessmentHTA of medical devices has drastically evolved over the past few decades. It is now well-established that medical device HTA differs to pharmaceuticals. This panel will discuss the past and present, of medical device value assessment, and how the HTA of medical devices needs to evolve towards 2020:  Will Medical Device HTA be Ready for the New Decade?
PN24 - Facing The Future By Facing Our HumanitiesBy considering HTA as more than a purely scientific process, HTA bodies may achieve greater value and relevance in their work and become better equipped to meet the challenges of the next decade. This panel session will consider the creative process of HTA, value judgements in emerging technologies, the changing understanding of evidence and increasing expectations of patients.
PN25 - Patient Participation In Core Outcome Set Development: Patient Experiences In coreHEM And coreNASHPanelists will be patients who participated in one of two Core Outcome Set initiatives, coreHEM and coreNASH. The panel will demonstrate how to prioritize patient opinions in the core outcome consensus process and how early alignment of outcomes can benefit HTA. The panel provides the opportunity for patients to describe their experiences as participants in the multi-stakeholder process.
PN26 - Tailoring Capacity Building To The African Context: Who And What Do We Need?This panel brings together speakers with experience in capacity building in Africa (including academia, global initiatives and the local setting) and other interested stakeholders to discuss ongoing activities and future directions that will support needs-based, fit-for-purpose and sustainable efforts going forward. It hopes to serve as a platform for exploring further potential for knowledge transfer and collaboration.

Panel sessions III: 15:15 – 16:30 Tuesday, June 18
PN05 - Social Media Analysis – An Essential Part Of HTA Beyond 2020?Social Media Analysis (SMA) offers great potential for understanding the needs and perspectives of patients and can provide a new source of patient-based evidence. To date though, its use in HTA has been limited. What needs to happen to unlock the potential of SMA in HTA? This panel will discuss and debate the opportunities and issues from different stakeholder perspectives.
PN27- Bridging The Gap Between HTA And Clinical Practice; A Novel Approach To Modeling Treatment SequencesPN27- Bridging The Gap Between HTA And Clinical Practice; A Novel Approach To Modeling Treatment Sequences
PN28 - One Requirement For All? Processing Of The Ethics Domain In HTA Reports For A German HTA-ProgrammeEthical aspects are supposed to be adequately considered in full health technology assessment (HTA) reports; in fact, they are often not considered at all or only to a minor extent. Based on the practical experiences of different author groups the panel will discuss points for both a pragmatic and methodologically well-founded processing of ethical aspects in HTA.
PN29 - Real-world Evidence In The Context Of Health Technology Assessment Processes-From Theory To ActionReal World Evidence (RWE) is not a new topic, but its emergence will present challenges and opportunities for relevant stakeholders involved in the production and use of HTA. The issues around the generation, analysis and use of RWE, may impact the way HTA is organised and produced, as well as the relation between traditional, and potentially new, stakeholders.
PN30 - Neglected Diseases, Neglected Patients, Neglected Health TechnologiesHealth technology definition embraces different type of technologies to manage diverse pathologies and different patients. However, most HTA organisations focus their activities to drugs assessment and to less extent to medical devices. This fact supposes a non-deniable imbalance that affects the level of information and awareness around different health technologies and how decisions on different health technologies are taken.
PN31 - Sharing Experiences In Setting Up An HTA OrganizationThe focus here is on different processes and structures necessary to establish HTA organizations in different health systems. This not only entails active engagement with key stakeholders at all stages of the HTA process for a continuous knowledge exchange of relevant issues, but also availability of effective educational and training programs as an integral building block to develop capacity.
PN32 - Uncertainty And Precision Medicine: Using Multi-Country Analyses In Health Technology AssessmentPrecision Medicine (PM) promises to revolutionize healthcare through biomarker discovery and individualized patient care. In its pursuit of individualization, PM amplifies evidentiary uncertainty for technologies that also have a significant impact on health care expenditures. We discuss how stakeholders can handle uncertainty when implementing PM. We focus on big data and multi-country health technology assessment.
PN33 - Regional And Country Case Studies On HTA And The Evolving Macro-system Of Decision-makingEnsuring synergies between regulatory and HTA processes can improve public health outcomes while promoting the rational allocation of scarce resources for health. Drawing on regional and country case studies from Eastern Europe, Eurasia, and Latin America, this session will explore the reasoning behind the implementation of HTA, its evolution, and envisioned opportunities for fostering alignment between these processes.
PN34 - Impact Of Patient Preferences On Trial Design – Implications For p-valuesIncorporating patient preferences into clinical trial design has focused on which outcomes are important to patients.  There has been less focus on the how specific outcomes and patients' acceptance of risk can influence trial designs, particularly p-values.  Should we move towards outcomes-specific p-values?  If so, what are implications for trial design, patient access, and health technology assessment?
PN35 - HTA, Social Preferences Measurement, And (Ultra) Rare Disorders: Social Cost Value Analysis For HTAHealth Technology Assessment (HTA) should reflect the social norms, preferences, and value judgments of the population. Measuring social preferences for HTA may require a payment vehicle different from the consumers’ perspective applied in most stated preference studies. New results of empirical studies designed to assess determinants of social value will be presented, and the far-reaching policy consequences will be discussed.
PN36 - What Insights Are Needed To Address Value In eHealth?For eHealth to increase value in health, its implementation must provide patient-centric care-pathways. The 2014/24 EU directive on public procurement provides opportunities, by encouraging the provision of the economically most advantageous solutions. Based on case studies, the panel questions what user involvement is needed for socio-economic and patient-considered value to emerge in publicly procured e-health developments.
PN37 - Integrating Patient Experience In Complex Pharmacological Solutions: Are The HTA Bodies Ready?Can patient experience be weighed properly in the HTA process, particularly in decision-making on complex technologies? This challenging topic will be debated by the proposed panel. Key aims are to address limitations of current HTA frameworks, and suggest new ways of integrating patient experience within technology assessment that go beyond standard, but inadequate, clinical and economic decision criteria.
PN38 - Qualitative Methods To Characterize Patient Preferences For Treatment Of Mitral Valve RegurgitationThe medical device industry is responding to increased desire for patient input by conducting patient preference studies.  These studies may evaluate patients’ treatment priorities, preference for treatment options, and/or risk tolerance for treatments with uncertain efficacy. This panel will discuss the value, methods, results, and implications of a qualitative preference study among patients with mitral valve regurgitation.
PN39 - Keep Calm and Carry On: INAHTA Members’ Views On Planning For Potentially Disruptive TechnologiesINAHTA member agencies present experiences assessing disruptive technologies and suggestions how to move from a reactive to a more proactive role in their identification.  Should disruptive technologies require a different approach to assessment? How can they be best identified and managed without compromising the guiding principles of evidence-based decision making? This panel session will explore these questions and more.

Panel sessions IV09:45 – 11:00 Wednesday, June 19
PN40 - Future Changes In Engagement With Clinicians In HTA? Perspectives From HTA-Agencies Across The GlobeAn international team of HTA-agencies presents an overview of how they engage with health care professionals and clinical experts. The benefits as well as the challenges of engaging with this stakeholder group will be discussed by panelists together with the audience. This panel will explore the potential of clinician engagement in HTA beyond 2020 in different parts of the world.
PN41 - Improving Efficiency Of Health Care And Promoting Innovation – Can HTA Combine These Two Agendas?De-adoption of wasteful interventions and promotion of effective innovations are universal objectives that have become increasingly relevant to healthcare systems internationally. This panel will explore the failures and successes of Health Technology Assessment programs that have operated in this field with the ultimate aim to amalgamate their experience in order to provide an informed method to approach this problem.
PN42 - Asian Perspectives On Patient Access To High Cost Medications: Can One Size Fit All?In an environment with ever expanding drug treatments for a wider array of diseases in smaller patient groups, the challenge is to balance access with ensuring drugs deliver substantive patient-important outcones. The panel will examine approaches (e.g. risk sharing agreements, managed entry agreements) from four Asian countries and discuss how transferable the processes might be between countries.
PN43 - Moving Towards HTA Institutionalisation In Africa: Lessons From GhanaDiscusses the wholistic experience of undertaking a multistakeholder summit in Africa. We will present the main technical findings of event's themes, capturing the interdisciplinary discussions that were carefully documented by a team of trained transcribers. Moreover, the panel will provide some insights on the event’s outcomes and short-intermediate term impact as a modelled approach for HTA networking and capacity building.
PN44 - Enhancing Value Frameworks And Decision-Making – Towards Evidence-Informed Deliberative ProcessesHealth technology assessment (HTA) practices employ value frameworks when making reimbursement decisions. Previous studies show that the application of some value frameworks may seriously comprise the legitimacy of reimbursement decisions. In this panel we discuss the added value of evidence-informed deliberative processes (EDPs) in order provide guidance to HTA organizations to improve their processes towards more legitimate decision-making.
PN45 - The Link Between HTA And Decision Making; Findings From The HTAi 2019 Latin America Policy ForumThe results from Health Technology Assessments (HTA) should be clearly linked to decision making. This can be challenging, and while the links may vary across different jurisdictions, they should always be transparent. The issues surrounding this in Latin America have been discussed at the HTAi Latin America Policy Forum; these will be presented and expanded on in this session.
PN46 - HTA Opportunities And Limitations In Low And Middle-Income Countries: Is There A Best Way Forward?For decision makers striving to implement UHC, HTA can be valuable to inform the allocation of resources. Most of the HTA methodology builds on experience of high income countries. LMICs can learn from experiences with HTA in those countries and consider alternatives to establish evidence-informed deliberative decision-making processes. Thereby local factors, stakeholder engagement and resources play an important role.
PN47 - GINAHTA: A Global Effort To Strengthen The Synergy Between HTA And Clinical Practice GuidelinesGINAHTA is a collaboration between the Guidelines International Network (G-I-N) and the International Network of Agencies for Health Technology Assessment (INAHTA). It was created to strengthen linkages between the guideline and HTA communities. This panel session will share learnings and practical guidance on cultivating effective collaboration between guideline developers and HTA producers to provide needed mutual benefit to all stakeholders.
PN48 - Enhancing The Value Of Patient Participation In HTA 2020: Patient Group Needs And HTA Body ActionsHow will patient participation in HTA evolve beyond 2020? In this panel, both patient groups and HTA bodies with experience of patient participation processes will see how their positions can be aligned to ensure that patient participation adds real value in HTA. Issues around patient group submissions, feedback and process development will be discussed to consider what’s needed beyond 2020.
PN49 - The Bottom Line: How Will Budget Impact Fit Into HTA 2020 And Beyond?This panel will involve a robust discussion of budget impact analysis for HTA decision-making in developing and developed countries, to understand whether current approaches are fit-for-purpose for joint assessments across geographies.  An interactive dialogue with the audience will focus on whether a uniform set of principles can be applied for budget impact assessment across countries.
PN50 - Sustainable Health Systems Beyond 2020: Meeting Health And Patient Needs In An Evolving LandscapeAn interactive Panel Discussion to explore how we can deliver sustainable health systems beyond 2020. An expert multi-stakeholder Panel will provide their insights from real-life examples on the role of patient engagement in facilitating the essential collaborative conversations that underpin delivery of a health system fit for the future.
PN51 - The Newcomer's Guide to HTA: An Introduction to the Handbook for Early Career NetworkThis panel session will provide an introduction to the newly launched Handbook for HTAi Early Career Network. Its aim is to guide newcomers to Health Technology Assessment (HTA), and to build capacity for HTA within health systems in order to improve health system outcomes through evidence informed approaches to access, appropriateness, availability, and affordability of health care services.
PN52 - Maximising The Value Of Expert Opinion In Rare DiseasesOrphan drugs are predicted to be 21.4 percent of worldwide prescription sales by 2022, therefore, establishing best practices for the evaluation of these treatments is crucial. This panel discusses the practical application of expert elicitation methods to maximise the value, transparency and reliability of the opinion used in the Health Technology Assessment (HTA) of orphan and ultra-orphan products across Europe.